BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2098 related articles for article (PubMed ID: 24060436)

  • 1. Downstaging disease in patients with hepatocellular carcinoma outside of Milan criteria: strategies using drug-eluting bead chemoembolization.
    Green TJ; Rochon PJ; Chang S; Ray CE; Winston H; Ruef R; Kreidler SM; Glueck DH; Shulman BC; Brown AC; Durham J
    J Vasc Interv Radiol; 2013 Nov; 24(11):1613-22. PubMed ID: 24060436
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transcatheter arterial chemoembolization with doxorubicin-eluting superabsorbent polymer microspheres in the treatment of hepatocellular carcinoma: midterm follow-up.
    Dekervel J; van Malenstein H; Vandecaveye V; Nevens F; van Pelt J; Heye S; Laleman W; Van Steenbergen W; Vaninbroukx J; Verslype C; Maleux G
    J Vasc Interv Radiol; 2014 Feb; 25(2):248-55.e1. PubMed ID: 24295569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of doxorubicin drug-eluting bead transarterial chemoembolization in patients with advanced hepatocellular carcinoma.
    Prajapati HJ; Dhanasekaran R; El-Rayes BF; Kauh JS; Maithel SK; Chen Z; Kim HS
    J Vasc Interv Radiol; 2013 Mar; 24(3):307-15. PubMed ID: 23375519
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of locoregional therapy before living donor liver transplantation in patients with hepatocellular carcinoma who meet the Milan criteria.
    Kim JM; Kwon CH; Joh JW; Choi MS; Lee JH; Koh KC; Paik SW; Kim GS; Kim SJ; Lee SK; Yoo BC
    Transplant Proc; 2012 Mar; 44(2):403-8. PubMed ID: 22410028
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conventional versus doxorubicin-eluting bead transarterial chemoembolization for hepatocellular carcinoma.
    Sacco R; Bargellini I; Bertini M; Bozzi E; Romano A; Petruzzi P; Tumino E; Ginanni B; Federici G; Cioni R; Metrangolo S; Bertoni M; Bresci G; Parisi G; Altomare E; Capria A; Bartolozzi C
    J Vasc Interv Radiol; 2011 Nov; 22(11):1545-52. PubMed ID: 21849247
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Downstaging and Bridging of Hepatocellular Carcinoma on Survival Following Liver Transplant: A Single Center Experience.
    Al Sebayel MI; Elsiesy H; Al-Hamoudi W; Alabbad S; ElSheikh Y; Elbeshbeshy H; Salih I; Yousif S; Saleh Y; Eldali A; Abaalkhail FA
    Exp Clin Transplant; 2017 Mar; 15(Suppl 2):7-11. PubMed ID: 28301992
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Degradable starch microspheres versus ethiodol and doxorubicin in transarterial chemoembolization of hepatocellular carcinoma.
    Niessen C; Unterpaintner E; Goessmann H; Schlitt HJ; Mueller-Schilling M; Wohlgemuth WA; Stroszczynski C; Wiggermann P
    J Vasc Interv Radiol; 2014 Feb; 25(2):240-7. PubMed ID: 24291001
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatocellular carcinoma downstaging in liver transplantation.
    Yu CY; Ou HY; Huang TL; Chen TY; Tsang LL; Chen CL; Cheng YF
    Transplant Proc; 2012 Mar; 44(2):412-4. PubMed ID: 22410030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transarterial Chemoembolization Using 100-μm Drug-Eluting Microspheres in Patients with Hepatocellular Carcinoma: A Prospective Study and Midterm Follow-up.
    Ou HY; Wu YN; Yu CY; Chen CL; Hsu HW; Weng CC; Leung-Chit Tsang L; Huang TL; Tong YS; Lim WX; Cheng YF
    J Vasc Interv Radiol; 2020 Nov; 31(11):1784-1791. PubMed ID: 33023805
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radiological response and inflammation scores predict tumour recurrence in patients treated with transarterial chemoembolization before liver transplantation.
    Nicolini D; Agostini A; Montalti R; Mocchegiani F; Mincarelli C; Mandolesi A; Robertson NL; Candelari R; Giovagnoni A; Vivarelli M
    World J Gastroenterol; 2017 May; 23(20):3690-3701. PubMed ID: 28611522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nine-year experience of doxorubicin-eluting beads chemoembolization for hepatocellular carcinoma.
    Cheung AH; Lam CS; Tam HS; Cheung TT; Pang R; Poon RT
    Hepatobiliary Pancreat Dis Int; 2016 Oct; 15(5):493-498. PubMed ID: 27733318
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preservation of quality of life with doxorubicin drug-eluting bead transarterial chemoembolization for unresectable hepatocellular carcinoma: Longitudinal prospective study.
    Xing M; Webber G; Prajapati HJ; Chen Z; El-Rayes B; Spivey JR; Pillai AA; Kim HS
    J Gastroenterol Hepatol; 2015 Jul; 30(7):1167-74. PubMed ID: 25675849
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transarterial chemoembolization with drug-eluting beads is effective for the maintenance of the Milan-in status in patients with a small hepatocellular carcinoma.
    Manini MA; Sangiovanni A; Martinetti L; Viganò D; La Mura V; Aghemo A; Iavarone M; Crespi S; Nicolini A; Colombo M
    Liver Transpl; 2015 Oct; 21(10):1259-69. PubMed ID: 26074360
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Korean Multicenter Registry of Transcatheter Arterial Chemoembolization with Drug-Eluting Embolic Agents for Nodular Hepatocellular Carcinomas: Six-Month Outcome Analysis.
    Lee M; Chung JW; Lee KH; Won JY; Chun HJ; Lee HC; Kim JH; Lee IJ; Hur S; Kim HC; Kim YJ; Kim GM; Joo SM; Oh JS
    J Vasc Interv Radiol; 2017 Apr; 28(4):502-512. PubMed ID: 27856136
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Doxorubicin-eluting bead vs conventional transcatheter arterial chemoembolization for hepatocellular carcinoma before liver transplantation.
    Nicolini D; Svegliati-Baroni G; Candelari R; Mincarelli C; Mandolesi A; Bearzi I; Mocchegiani F; Vecchi A; Montalti R; Benedetti A; Risaliti A; Vivarelli M
    World J Gastroenterol; 2013 Sep; 19(34):5622-32. PubMed ID: 24039354
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and feasibility of same-day discharge of patients with unresectable hepatocellular carcinoma treated with doxorubicin drug-eluting bead transcatheter chemoembolization.
    Prajapati HJ; Rafi S; El-Rayes BF; Kauh JS; Kooby DA; Kim HS
    J Vasc Interv Radiol; 2012 Oct; 23(10):1286-93.e1. PubMed ID: 22999748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Downstaging Outcomes for Hepatocellular Carcinoma: Results From the Multicenter Evaluation of Reduction in Tumor Size before Liver Transplantation (MERITS-LT) Consortium.
    Mehta N; Frenette C; Tabrizian P; Hoteit M; Guy J; Parikh N; Ghaziani TT; Dhanasekaran R; Dodge JL; Natarajan B; Holzner ML; Frankul L; Chan W; Fobar A; Florman S; Yao FY
    Gastroenterology; 2021 Nov; 161(5):1502-1512. PubMed ID: 34331914
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Section 3. Current status of downstaging of hepatocellular carcinoma before liver transplantation.
    Sharr WW; Chan SC; Lo CM
    Transplantation; 2014 Apr; 97 Suppl 8():S10-7. PubMed ID: 24849822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic factors for survival in patients with unresectable hepatocellular carcinoma undergoing chemoembolization with doxorubicin drug-eluting beads: a preliminary study.
    Dhanasekaran R; Kooby DA; Staley CA; Kauh JS; Khanna V; Kim HS
    HPB (Oxford); 2010 Apr; 12(3):174-80. PubMed ID: 20590884
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early Prediction of the Outcome Using Tumor Markers and mRECIST in Unresectable Hepatocellular Carcinoma Patients Who Underwent Transarterial Chemoembolization.
    Ichikawa T; Machida N; Sasaki H; Tenmoku A; Kaneko H; Negishi R; Oi I; Fujino MA
    Oncology; 2016; 91(6):317-330. PubMed ID: 27784014
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 105.